Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 Operating Cash Flow per Share is $0.05 as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 647 Medical Devices & Instruments companies, NIOX Group ranks better than 75.27% on this metric.
NIOX Group's operating cash flow per share for the
six
months ended in Dec. 2025 was $0.03.
NIOX Group's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of NIOX Group was -5.30% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 33.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for NIOX Group's Operating Cash Flow per Share or its related term are showing as below:
CSSPF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -42.7 Med: 19.2 Max: 133.1
Current: 33.9
During the past 13 years, NIOX Group's highest 3-Year average Operating Cash Flow per Share Growth Rate was 133.10% per year. The lowest was -42.70% per year. And the median was 19.20% per year.
CSSPF's 3-Year OCF Growth Rate is ranked better than 75.27% of 647
companies
in the Medical Devices & Instruments industry
Industry Median: 12.3
vs CSSPF: 33.90
NIOX Group Operating Cash Flow per Share Related Terms
NIOX Group Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for NIOX Group's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Operating Cash Flow per Share Comparison
For the Medical Devices subindustry, NIOX Group's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where NIOX Group's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.05 mean?
NIOX Group (CSSPF) has a Operating Cash Flow per Share of $0.05 as of Dec. 2025. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #160 out of 647 companies in the Medical Devices & Instruments industry, placing it in the top 24.7%.
Is NIOX Group's Operating Cash Flow per Share too high?
NIOX Group's current Operating Cash Flow per Share is $0.05. The Medical Devices & Instruments industry median Operating Cash Flow per Share is 12.30. NIOX Group's value of $0.05 is 99.6% below this industry median. Based on the distribution chart, NIOX Group ranks #160 out of 647 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Operating Cash Flow per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #160 out of 647 companies for Operating Cash Flow per Share. This places NIOX Group in the top 25% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 12.30. NIOX Group's value of $0.05 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.30, based on 647 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Operating Cash Flow per Share of $0.05 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Operating Cash Flow per Share is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.82 — trading 32.2% below its estimated fair value. The current Operating Cash Flow per Share is $0.05 and 99.6% below the Medical Devices & Instruments industry median of 12.30. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Operating Cash Flow per Share is $0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.82 is trading 32.2% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Operating Cash Flow per Share: $0.05
GF Value™: $1.21 vs. price of $0.82 (32.2% below fair value)
Industry Position: 99.6% below the Medical Devices & Instruments median (#160 of 647)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
